A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...